In various solid tumors, including hepatocellular carcinoma, breast cancer, gastric cancer, and lung cancer, aberrant RBM15 expression has been correlated with enhanced proliferation, resistance to apoptosis, increased metastatic potential, and poor patient prognosis (Cao et al., 2024). Here, RBM15 is linked to gastric cancer.